my primary research focused on drug resistance of hematologic malignancies, particularly in multiple myeloma (MM), studying the mechanisms of resistance to immune-targeted therapies and identifying novel targets for anti-tumor drugs. I mainly utilized the CRISPR-Cas9 screen system, combined with mouse model in vivo to explore the genes related to the regulation of tumor cell resistance to different anti-tumor drugs under different treatment conditions, and to clarify the molecular mechanism, providing a preclinical theoretical basis for the establishment of strategies to reverse tumor drug resistance and effectively promotes the clinical transformation of related programs in the treatment of MM. Additionally, based on newly discovered anti-tumor targets, designing new drugs to treat cancer.
Shandong Cancer Hospital and Institute
Jinan, Shandong, China